140 related articles for article (PubMed ID: 8620524)
1. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 1996 Feb; 42(2):81-7. PubMed ID: 8620524
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
[TBL] [Abstract][Full Text] [Related]
3. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
Frödin JE; Faxas ME; Hagström B; Lefvert AK; Masucci G; Nilsson B; Steinitz M; Unger P; Mellstedt H
Hybridoma; 1991 Aug; 10(4):421-31. PubMed ID: 1937495
[TBL] [Abstract][Full Text] [Related]
4. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
Fagerberg J; Frödin JE; Wigzell H; Mellstedt H
Cancer Immunol Immunother; 1993 Sep; 37(4):264-70. PubMed ID: 8348565
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
6. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?
Fagerberg J; Frödin JE; Ragnhammar P; Steinitz M; Wigzell H; Mellstedt H
Cancer Immunol Immunother; 1994 Mar; 38(3):149-59. PubMed ID: 8124683
[TBL] [Abstract][Full Text] [Related]
7. Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the "internal image of the antigen" (ab2).
Mellstedt H; Frödin JE; Biberfeld P; Fagerberg J; Giscombe R; Hernandez A; Masucci G; Li SL; Steinitz M
Int J Cancer; 1991 May; 48(3):344-9. PubMed ID: 2040527
[TBL] [Abstract][Full Text] [Related]
8. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer.
Herlyn D; Somasundaram R; Zaloudik J; Jacob L; Harris D; Kieny MP; Sears H; Mastrangelo M
Cell Biophys; 1994; 24-25():143-53. PubMed ID: 7736518
[TBL] [Abstract][Full Text] [Related]
9. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.
Wettendorff M; Iliopoulos D; Tempero M; Kay D; DeFreitas E; Koprowski H; Herlyn D
Proc Natl Acad Sci U S A; 1989 May; 86(10):3787-91. PubMed ID: 2786203
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the anti-idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits.
Comacchio RM; Bradley J; Hohmann AW
Immunol Cell Biol; 1996 Feb; 74(1):72-80. PubMed ID: 8934657
[TBL] [Abstract][Full Text] [Related]
11. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients.
Birebent B; Koido T; Mitchell E; Li W; Somasundaram R; Purev E; Hoey D; Mastrangelo M; Maguire H; Harris DT; Nair S; Cai E; Herlyn D
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R27-33. PubMed ID: 11768621
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients.
Herlyn D; Harris D; Zaloudik J; Sperlagh M; Maruyama H; Jacob L; Kieny MP; Scheck S; Somasundaram R; Hart E
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):303-11. PubMed ID: 8061902
[TBL] [Abstract][Full Text] [Related]
13. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.
Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H
Cancer Res; 1995 May; 55(9):1824-7. PubMed ID: 7728746
[TBL] [Abstract][Full Text] [Related]
14. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
[TBL] [Abstract][Full Text] [Related]
15. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.
Fagerberg J; Steinitz M; Wigzell H; Askelöf P; Mellstedt H
Proc Natl Acad Sci U S A; 1995 May; 92(11):4773-7. PubMed ID: 7539133
[TBL] [Abstract][Full Text] [Related]
16. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cancer patients' immune responses by anti-idiotypic antibodies.
Herlyn D; Wettendorff M; Koprowski H
Int Rev Immunol; 1989; 4(4):347-57. PubMed ID: 2519932
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
Maruyama H; Zaloudik J; Li W; Sperlagh M; Koido T; Somasundaram R; Scheck S; Prewett M; Herlyn D
Cancer Immunol Immunother; 2000 Jun; 49(3):123-32. PubMed ID: 10881691
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
